Chronic Insomnia Disorder Is Among Should Take Measures to Discuss Sleep the Most Widely Reported Clinical Con- Problems and Their Impact on The

Total Page:16

File Type:pdf, Size:1020Kb

Chronic Insomnia Disorder Is Among Should Take Measures to Discuss Sleep the Most Widely Reported Clinical Con- Problems and Their Impact on The Review Article Address correspondence to Dr Alon Y. Avidan, University of California Los Angeles, Chronic Insomnia David Geffen School of Medicine, Reed Neurological Research Center, 710 Disorder Westwood Blvd, C153, Los Angeles, CA 90095-1769, [email protected]. Alon Y. Avidan, MD, MPH, FAAN; David N. Neubauer, MD Relationship Disclosure: Dr Avidan has received personal compensation for ABSTRACT serving as a speaker for Arbor Pharmaceuticals and PERNIX Purpose of Review: Neurologists, along with all health care providers, commonly Therapeutics and receives encounter patients with insomnia, which is a condition that impacts patients’ royalties from Elsevier and underlying neurologic conditions in a bidirectional manner. While chronic insomnia UpToDate, Inc. Dr Neubauer has received personal is one of the most common sleep disturbances, only a small proportion of individuals compensation for serving on with this condition discuss their sleep problems with their providers. When insomnia is the board of directors for the described, it is more often in relationship to another medical problem, as opposed to National Sleep Foundation, as a consultant for Purdue an independent condition. In neurology practice, multiple factors including pain, Pharma LP, and as a lecturer movement disorders, sleep apnea, and medications that act on the central nervous for the American Academy of system often contribute to insomnia. An all-inclusive approach is necessary when Sleep Medicine, the American College of Chest Physicians, evaluating sleep problems in patients with insomnia. the Clayton Sleep Institute, the Recent Findings: The US Food and Drug Administration (FDA) has approved several New Jersey Sleep Society, and medications for the treatment of insomnia that target specific receptor systems in the the US Psychiatric and Mental Health Congress. brain and incorporate several unique pharmacodynamic and pharmacokinetic profiles Unlabeled Use of that can represent customized therapy for specific insomnia phenotypes. FDA-approved Products/Investigational medications for insomnia include +-aminobutyric acid (GABA)-modulating benzodiaz- Use Disclosure: epine receptor agonists, a melatonin receptor agonist, a histamine receptor antagonist, Drs Avidan and Neubauer discuss the off-label uses of and the newest approved option, a hypocretin (orexin) receptor antagonist. various central nervous Summary: This article provides an evidence-based multidisciplinary approach to the Y system acting medications treatment of insomnia, highlighting the rationale and utility of cognitive-behavioral for insomnia, which include sedating antidepressants such therapy and pharmacologic interventions. Neurologists should be proactive in assessing as amitriptyline, doxepin, the impact of underlying comorbidities on insomnia, particularly in the setting of mirtazapine, and trazodone; psychiatric conditions such as depression, sleep disorders such as circadian rhythm the antipsychotic quetiapine; antihistamine compounds disorders, and medical problems such as nocturia. such as doxylamine; medications available over-the-counter marketed as Continuum (Minneap Minn) 2017;23(4):1064–1092. sleep aids as single compounds or as a combination therapy with analgesics (acetaminophen INTRODUCTION ditions in medicine and has a signifi- or ibuprofen); and dietary Insomnia is pervasive in neurology prac- cant impact on populations treated in supplement sleep aids such as 1,2 chamomile, hops, kava kava, tice, but is often undiagnosed and neurology practices. Sleep difficulties melatonin, passionflower, tart untreated. Specific patient cohorts such often result from multiple etiologies and cherry juice, and valerian. * 2017 American Academy as older adults, patients who live in may require a multidisciplinary treat- of Neurology. nursing homes, and individuals with ment approach based on established underlying chronic comorbid medical, evaluation guidelines and evidence- neurologic, and psychiatric disorders based therapies.3 Recent evidence dem- are particularly at risk. These patients onstrates that poor sleep is associated often present with difficulties falling with a wide range of negative health asleep and maintaining sleep and expe- outcomes and that poorer quality of rience significant daytime consequences life and medical, neurologic, and psy- such as fatigue, memory problems, and chiatric comorbidities disrupt sleep. poor psychosocial function. Given this bidirectionality, neurologists Chronic insomnia disorder is among should take measures to discuss sleep the most widely reported clinical con- problems and their impact on the 1064 ContinuumJournal.com August 2017 Copyright © American Academy of Neurology. Unauthorized reproduction of this article is prohibited. KEY POINTS underlying neurologic disease and take Several classification systems offer h Recent evidence specific steps toward enhancing sleep criteria for insomnia nosologies and demonstrates that poor quantity and quality in their patients. specific insomnia phenotypes. Insom- sleep is associated with By doing so, the clinician may have a nia classification schemes are outlined a wide range of broader role in promoting wellness by the International Classification of negative health and bringing about improvements in Diseases, Tenth Revision (ICD-10) and outcomes and that some comorbid conditions as well. the Diagnostic and Statistical Manual poorer quality of life and of Mental Disorders, Fifth Edition medical, neurologic, DEFINITION OF INSOMNIA (DSM-5), which is the American Psy- and psychiatric Insomnia disorder refers to persistent chiatric Association’s 2013 update to its comorbidities disrupt difficulties falling asleep, maintaining classification and diagnostic tool.6,7 sleep. sleep, or waking up earlier than habitual Both the ICD-10 and DSM-5 assimilate h Insomnia disorder refers rise time and is associated with impair- categorizations of key sleep disorders to persistent difficulties ment of daytime functioning despite including various insomnia subtypes. falling asleep, the opportunity for sufficient sleep The 2014 American Academy of Sleep maintaining sleep, or waking up earlier than duration.4 Although patients with in- Medicine (AASM) International Classi- habitual rise time and is somnia report the chronicity of wake- fication of Sleep Disorders, Third Edi- associated with fulness during the night, insomnia tion (ICSD-3) defines general criteria impairment of daytime disorder is conceptualized to represent for chronic insomnia disorder, reviewed functioning despite a 24-hour condition reflecting a state of in Table 8-1,aswellasshort-term the opportunity for 4 hyperarousal leading to both the night- insomnia disorder. The chronic and sufficient sleep time and daytime symptomatology.5 short-term insomnia disorder criteria duration. a TABLE 8-1 Diagnostic Criteria for Chronic Insomnia Disorder Criteria A through F are required for a diagnosis of chronic insomnia disorder A. The patient/family members/caregiver reports or observes one or more of the following 1. Difficulties with sleep initiation 2. Difficulties with sleep maintenance 3. Waking up earlier than desired with difficulties reinitiating sleep 4. Opposition to going to bed during habitual bedtime schedule 5. Difficulties sleeping without the intervention of the parent or caregiver B. The patient/patient’s parent/caregiver report or observe one or more of the following difficulties in relationship to the nighttime sleep difficulty 1. Malaise/fatigue 2. Impairment in concentration, attention, or memory 3. Impairment in domains of social function, fulfillment of family duties, or difficulties with occupational or academic performance 4. Disturbances in mood and/or irritability 5. Excessive daytime somnolence 6. Problems with behavioral function (eg, aggression, hyperactivity, impulsivity) 7. Impairment in motivation/energy/initiative 8. Proneness for accidents and/or errors 9. Concerns about or dissatisfaction with sleep quality Continued on page 1066 Continuum (Minneap Minn) 2017;23(4):1064–1092 ContinuumJournal.com 1065 Copyright © American Academy of Neurology. Unauthorized reproduction of this article is prohibited. Chronic Insomnia Disorder a TABLE 8-1 Diagnostic Criteria for Chronic Insomnia Disorder Continued from page 1065 C. The reported sleep/wake difficulties cannot be otherwise explained by inadequate opportunity or inadequate circumstances for sleep (ie, the patients should have sufficient allotted time for sleep and environmental conditions are conducive for sleep [safe, dark, quiet, and comfortable]). D. Frequency criteria: The sleep difficulties and associated daytime symptoms must occur at a frequency of at least 3 times per week. E. Duration criteria: The sleep disturbance and the associated daytime symptoms must be present at least 3 months. F. The sleep/wake disturbance is not attributed to or explained by another underlying primary sleep disorder (such as obstructive sleep apnea, circadian rhythm sleep-wake disorder, or a motor disorder of sleep). Notes 1. Insomnia may be observed across all age groups. Opposition to going to bed on a proper schedule and difficulty sleeping without a parent or in the absence of a caregiver intervention is seen most commonly in children and older adults who require the supervision of a caretaker due to a significant disturbance in cognitive or functional impairment (eg, patients with underlying neurodegenerative diseases such as Alzheimer dementia). 2. A unique circumstance occurs when
Recommended publications
  • ON ATTRACTION of SLIME MOULD PHYSARUM POLYCEPHALUM to PLANTS with SEDATIVE PROPERTIES 1. Introduction Physarum Polycephalum Belo
    ON ATTRACTION OF SLIME MOULD PHYSARUM POLYCEPHALUM TO PLANTS WITH SEDATIVE PROPERTIES ANDREW ADAMATZKY Abstract. A plasmodium of acellular slime mould Physarum polycephalum is a large single cell with many nuclei. Presented to a configuration of attracting and repelling stimuli a plasmodium optimizes its growth pattern and spans the attractants, while avoiding repellents, with efficient network of protoplasmic tubes. Such behaviour is interpreted as computation and the plasmodium as an amorphous growing biologi- cal computer. Till recently laboratory prototypes of slime mould computing devices (Physarum machines) employed rolled oats and oat powder to represent input data. We explore alternative sources of chemo-attractants, which do not require a sophis- ticated laboratory synthesis. We show that plasmodium of P. polycephalum prefers sedative herbal tablets and dried plants to oat flakes and honey. In laboratory experi- ments we develop a hierarchy of slime-moulds chemo-tactic preferences. We show that Valerian root (Valeriana officinalis) is strongest chemo-attractant of P. polycephalum outperforming not only most common plants with sedative activities but also some herbal tablets. Keywords: Physarum polycephalum, slime mould, valerian, passion flower, hops, ver- vain, gentian, wild lettuce, chemo-attraction 1. Introduction Physarum polycephalum belongs to the species of order Physarales, subclass Myxo- gastromycetidae, class Myxomycetes, division Myxostelida. It is commonly known as a true, acellular or multi-headed slime mould. Plasmodium is a `vegetative' phase, single cell with a myriad of diploid nuclei. The plasmodium looks like an amorphous yellowish mass with networks of protoplasmic tubes. The plasmodium behaves and moves as a giant amoeba. It feeds on bacteria, spores and other microbial creatures and micro- particles (Stephenson & Stempen, 2000).
    [Show full text]
  • Yerevan State Medical University After M. Heratsi
    YEREVAN STATE MEDICAL UNIVERSITY AFTER M. HERATSI DEPARTMENT OF PHARMACY Balasanyan M.G. Zhamharyan A.G. Afrikyan Sh. G. Khachaturyan M.S. Manjikyan A.P. MEDICINAL CHEMISTRY HANDOUT for the 3-rd-year pharmacy students (part 2) YEREVAN 2017 Analgesic Agents Agents that decrease pain are referred to as analgesics or as analgesics. Pain relieving agents are also called antinociceptives. An analgesic may be defined as a drug bringing about insensibility to pain without loss of consciousness. Pain has been classified into the following types: physiological, inflammatory, and neuropathic. Clearly, these all require different approaches to pain management. The three major classes of drugs used to manage pain are opioids, nonsteroidal anti-inflammatory agents, and non opioids with the central analgetic activity. Narcotic analgetics The prototype of opioids is Morphine. Morphine is obtained from opium, which is the partly dried latex from incised unripe capsules of Papaver somniferum. The opium contains a complex mixture of over 20 alkaloids. Two basic types of structures are recognized among the opium alkaloids, the phenanthrene (morphine) type and the benzylisoquinoline (papaverine) type (see structures), of which morphine, codeine, noscapine (narcotine), and papaverine are therapeutically the most important. The principle alkaloid in the mixture, and the one responsible for analgesic activity, is morphine. Morphine is an extremely complex molecule. In view of establish the structure a complicated molecule was to degrade the: compound into simpler molecules that were already known and could be identified. For example, the degradation of morphine with strong base produced methylamine, which established that there was an N-CH3 fragment in the molecule.
    [Show full text]
  • Receives Fda Approval for the Treatment of Insomnia
    AMBIEN CR™ (ZOLPIDEM TARTRATE EXTENDED-RELEASE TABLETS) CIV RECEIVES FDA APPROVAL FOR THE TREATMENT OF INSOMNIA First and Only Extended-Release Prescription Sleep Medication Indicated for Sleep Induction and Maintenance Covers Broad Insomnia Population Paris, France, September 6, 2005 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has approved AMBIEN CR™ (zolpidem tartrate extended-release tablets) CIV, a new extended-release formulation of the number ® one prescription sleep aid, AMBIEN (zolpidem tartrate) CIV, for the treatment of insomnia. AMBIEN CR is non-narcotic and a non-benzodiazepine, formulated to offer a similar safety profile to AMBIEN with a new indication for sleep maintenance, in addition to sleep induction. AMBIEN CR is the first and only extended-release prescription sleep medication to help people with insomnia fall asleep fast and maintain sleep with no significant decrease in next day performance. AMBIEN CR, a bi-layered tablet, is delivered in two stages. The first layer dissolves quickly to induce sleep. The second layer is released more gradually into the body to help provide more continuous sleep. “Insomnia is a significant public health problem, affecting millions of Americans. Insomnia impacts daily activities and is associated with increased health care costs,” said James K. Walsh, PhD, Executive Director and Senior Scientist, Sleep Medicine and Research Center at St. Luke's Hospital in St. Louis, Missouri. “Helping patients stay asleep is recognized as being as important as helping them fall asleep,” said Walsh. “Ambien CR has shown evidence of promoting sleep onset and more continuous sleep".
    [Show full text]
  • Herbal Remedies and Their Possible Effect on the Gabaergic System and Sleep
    nutrients Review Herbal Remedies and Their Possible Effect on the GABAergic System and Sleep Oliviero Bruni 1,* , Luigi Ferini-Strambi 2,3, Elena Giacomoni 4 and Paolo Pellegrino 4 1 Department of Developmental and Social Psychology, Sapienza University, 00185 Rome, Italy 2 Department of Neurology, Ospedale San Raffaele Turro, 20127 Milan, Italy; [email protected] 3 Sleep Disorders Center, Vita-Salute San Raffaele University, 20132 Milan, Italy 4 Department of Medical Affairs, Sanofi Consumer HealthCare, 20158 Milan, Italy; Elena.Giacomoni@sanofi.com (E.G.); Paolo.Pellegrino@sanofi.com (P.P.) * Correspondence: [email protected]; Tel.: +39-33-5607-8964; Fax: +39-06-3377-5941 Abstract: Sleep is an essential component of physical and emotional well-being, and lack, or dis- ruption, of sleep due to insomnia is a highly prevalent problem. The interest in complementary and alternative medicines for treating or preventing insomnia has increased recently. Centuries-old herbal treatments, popular for their safety and effectiveness, include valerian, passionflower, lemon balm, lavender, and Californian poppy. These herbal medicines have been shown to reduce sleep latency and increase subjective and objective measures of sleep quality. Research into their molecular components revealed that their sedative and sleep-promoting properties rely on interactions with various neurotransmitter systems in the brain. Gamma-aminobutyric acid (GABA) is an inhibitory neurotransmitter that plays a major role in controlling different vigilance states. GABA receptors are the targets of many pharmacological treatments for insomnia, such as benzodiazepines. Here, we perform a systematic analysis of studies assessing the mechanisms of action of various herbal medicines on different subtypes of GABA receptors in the context of sleep control.
    [Show full text]
  • Sleep Disturbance in MS
    SLEEP DISTURBANCE AND MULTIPLE SCLEROSIS Abbey J. Hughes, PhD Department of Rehabilitation Medicine University of Washington School of Medicine Table of Contents Introduction ................................................................................................................................................................ 2 Summary of MS Sleep Research .......................................................................................................................... 3 Emerging Treatments for Sleep Disturbance in MS .................................................................................... 6 Tips for Assessing Your Sleep – Worksheet .................................................................................................. 8 Additional Tools and Resources.......................................................................................................................... 9 References ................................................................................................................................................................ 10 1 Introduction Multiple sclerosis (MS) is a chronic disease characterized by loss of myelin (demyelination) and damage to nerve fibers (neurodegeneration) in the central nervous system (CNS). MS is associated with a diverse range of physical, cognitive, emotional, and behavioral symptoms, and can significantly interfere with daily functioning and overall quality of life. MS directly impacts the CNS by causing demyelinating lesions, or plaques, in the brain,
    [Show full text]
  • 2 ? Obesity and Sleep- Disordered Breathing
    Review series Obesity and the lung: 2 ? Obesity and sleep- Thorax: first published as 10.1136/thx.2007.086843 on 28 July 2008. Downloaded from disordered breathing F Crummy,1 A J Piper,2 M T Naughton3 1 Regional Respiratory Centre, ABSTRACT include excessive daytime sleepiness, unrefreshing Belfast City Hospital, Belfast, 2 As the prevalence of obesity increases in both the sleep, nocturia, loud snoring (above 80 dB), wit- UK; Royal Prince Alfred developed and the developing world, the respiratory nessed apnoeas and nocturnal choking. Signs Hospital, Woolcock Institute of Medical Research, University of consequences are often underappreciated. This review include systemic (or difficult to control) hyperten- Sydney, Sydney, New South discusses the presentation, pathogenesis, diagnosis and sion, premature cardiovascular disease, atrial fibril- Wales, Australia; 3 General management of the obstructive sleep apnoea, overlap and lation and heart failure.8 The obstructive sleep Respiratory and Sleep Medicine, obesity hypoventilation syndromes. Patients with these apnoea syndrome (OSAS) is arbitrarily defined by Department of Allergy, Immunology and Respiratory conditions will commonly present to respiratory physi- .5 apnoeas or hypopnoeas per hour plus symp- Medicine, Alfred Hospital and cians, and recognition and effective treatment have toms of daytime sleepiness. Monash University, Melbourne, important benefits in terms of patient quality of life and Almost 20 years ago the prevalence of OSA and Victoria, Australia reduction in healthcare
    [Show full text]
  • Insomnia in the Elderly: Update on Assessment and Management
    To see other CME articles, go to: www.cmegeriatrics.ca www.geriatricsjournal.ca If you are interested in receiving this publication on a regular basis, please consider becoming a member. INSOMNIA IN THE ELDERLY: UPDATE ON ASSESSMENT AND MANAGEMENT Canadian Geriatrics Society Abstract Insomnia disorder is one of the most common sleep-wake disorders seen Soojin Chun in the geriatric population, and is associated with multiple psychiatric MSc., MD FRCP(C) and medical consequences. Insomnia is a subjective complaint of Geriatric Psychiatry difficulty falling and/or staying asleep, or experiencing non-restorative Subspecialty Resident sleep, associated with significant daytime consequences including (PGY-6), University of difficulty concentrating, fatigue and mood disturbances. There is no Ottawa single diagnostic tool to assess insomnia. Consequently, an insomnia assessment requires thorough history taking including a sleep inquiry, Elliott Kyung Lee medical history, psychiatric history, substance use history and a relevant MD, FRCP(C), D. ABPN physical examination. Insomnia is often multifactorial in origin, and Sleep Med, Addiction routinely is associated with multiple other psychiatric and medical Psych, D. ABSM, F. AASM, disorders. Therefore, predisposing, precipitating and perpetuating factors F. APA, Sleep Specialist, must be carefully examined in the context of an evaluation of insomnia Royal Ottawa Mental symptoms. Other specific sleep assessments (e.g., overnight Health Centre, Assistant polysomnography) can be completed to rule out other sleep-wake Professor, University of disorders. For management, a cognitive-behavioural approach (including Ottawa sleep restriction therapy, stimulus control therapy) is commonly accepted as an effective, first-line treatment for insomnia disorder. Corresponding Author: A brief version of CBT-I focusing on behavioural interventions (Brief Elliott Kyung Lee Behavioural Treatment of Insomnia, BBT-I) has also demonstrated efficacy in the geriatric patient population.
    [Show full text]
  • Respiratory Mechanics and Ventilatory Control in Overlap Syndrome and Obesity Hypoventilation Johan Verbraecken1* and Walter T Mcnicholas2,3
    Verbraecken and McNicholas Respiratory Research 2013, 14:132 http://respiratory-research.com/content/14/1/132 REVIEW Open Access Respiratory mechanics and ventilatory control in overlap syndrome and obesity hypoventilation Johan Verbraecken1* and Walter T McNicholas2,3 Abstract The overlap syndrome of obstructive sleep apnoea (OSA) and chronic obstructive pulmonary disease (COPD), in addition to obesity hypoventilation syndrome, represents growing health concerns, owing to the worldwide COPD and obesity epidemics and related co-morbidities. These disorders constitute the end points of a spectrum with distinct yet interrelated mechanisms that lead to a considerable health burden. The coexistence OSA and COPD seems to occur by chance, but the combination can contribute to worsened symptoms and oxygen desaturation at night, leading to disrupted sleep architecture and decreased sleep quality. Alveolar hypoventilation, ventilation-perfusion mismatch and intermittent hypercapnic events resulting from apneas and hypopneas contribute to the final clinical picture, which is quite different from the “usual” COPD. Obesity hypoventilation has emerged as a relatively common cause of chronic hypercapnic respiratory failure. Its pathophysiology results from complex interactions, among which are respiratory mechanics, ventilatory control, sleep-disordered breathing and neurohormonal disturbances, such as leptin resistance, each of which contributes to varying degrees in individual patients to the development of obesity hypoventilation. This respiratory embarrassment takes place when compensatory mechanisms like increased drive cannot be maintained or become overwhelmed. Although a unifying concept for the pathogenesis of both disorders is lacking, it seems that these patients are in a vicious cycle. This review outlines the major pathophysiological mechanisms believed to contribute to the development of these specific clinical entities.
    [Show full text]
  • A Acetylcholine Anticholinergic Drugs, 49 Cholinergic Wake-Promoting
    Index A C Acetylcholine Cataplexy anticholinergic drugs, 49 GHB, 37 cholinergic wake-promoting system, 48 narcolepsy type 1, 215 cholinesterase inhibitors, 48–49 narcolepsy type 2, 215 milameline, 49 sleep-promoting orexinergic inhibitors, 46 nicotine, 49 SXB, 238–240 receptors, 48 tricyclic antidepressants, 253 sleep-promoting cholinergic Cell replacement therapy, 253 inhibitors, 49 Central sleep apnea (CSA) syndrome, 76 Adenosine Cheyne–Stokes breathing (CSB), 76 adenosine-mediated sleep-promoting Cholinesterase inhibitors system, 41 donepezil, 49 receptors, 42 physostigmine, 48 sleep-promoting adenosine receptor Chronic insomnia agonists, 42 dose discrimination, lack of, 168 wake-promoting adenosine receptor psychiatric comorbidities, 169 antagonists, 42 short-term efficacy and long-term safety, Amantadine, 77 167–168 Armodafinil sleep induction and maintenance, 168–169 chemical structure, 212 Chronic obstructive sleep apnea multiple sclerosis, 222 (OSA), 178–179 narcolepsy, 218 Chronic primary insomnia obstructive sleep apnea, 219–221 adverse effects, 165, 167 pharmacokinetics, 214 comorbid psychiatric disorders, 164 R enantiomer, 213 double-blind trial, 164 safety, 224–225 efficacy, 165 shift work disorder, 223 long-term trial, 165 open-label extension phase, 165 post hoc analysis, 165–166 B psychomotor performance, 164–165 Benzodiazepine Withdrawal Symptom rebound insomnia, 164 Questionnaire (BWSQ), 183 WASO, 164–165 © Springer International Publishing Switzerland 2015 289 A. Guglietta (ed.), Drug Treatment of Sleep Disorders, Milestones
    [Show full text]
  • Insomnia in Adults
    New Guideline February 2017 The AASM has published a new clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults. These new recommendations are based on a systematic review of the literature on individual drugs commonly used to treat insomnia, and were developed using the GRADE methodology. The recommendations in this guideline define principles of practice that should meet the needs of most adult patients, when pharmacologic treatment of chronic insomnia is indicated. The clinical practice guideline is an essential update to the clinical guideline document: Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307–349. SPECIAL ARTICLE Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults Sharon Schutte-Rodin, M.D.1; Lauren Broch, Ph.D.2; Daniel Buysse, M.D.3; Cynthia Dorsey, Ph.D.4; Michael Sateia, M.D.5 1Penn Sleep Centers, Philadelphia, PA; 2Good Samaritan Hospital, Suffern, NY; 3UPMC Sleep Medicine Center, Pittsburgh, PA; 4SleepHealth Centers, Bedford, MA; 5Dartmouth-Hitchcock Medical Center, Lebanon, NH Insomnia is the most prevalent sleep disorder in the general popula- and disease management of chronic adult insomnia, using existing tion, and is commonly encountered in medical practices. Insomnia is evidence-based insomnia practice parameters where available, and defined as the subjective perception of difficulty with sleep initiation, consensus-based recommendations to bridge areas where such pa- duration, consolidation, or quality that occurs despite adequate oppor- rameters do not exist.
    [Show full text]
  • Antibiotic-Induced Depletion of the Gut Microbiota Reduces Nocturnal Sleep in Mice
    bioRxiv preprint doi: https://doi.org/10.1101/199075; this version posted October 5, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Sleep and the gut microbiome: antibiotic-induced depletion of the gut microbiota reduces nocturnal sleep in mice Jonathan Lendrum1, a, *, Bradley Seebach1, Barrett Klein1, Sumei Liu1 1Department of Biology, University of Wisconsin – La Crosse, 1725 State St, La Crosse, WI 54601, USA aCorrespondence (J. Lendrum): Tel: +1(920)-850-7883. E-mail: [email protected] *Permanent Address (J. Lendrum): 5600 11th Ave S, Minneapolis, MN 55417, USA Highlights -14 d broad-spectrum antibiotic treatment effectively depletes the gut microbiota. -Gut microbiota depletion reduces nocturnal sleep, but not diurnal sleep. -Gut microbiota depletion increases nocturnal locomotion, but not diurnal locomotion. -Antibiotics may be insomnogenic: implications for idiopathic sleep disorders. Abstract Several bacterial cell wall components such as peptidoglycan and muramyl peptide are potent inducers of mammalian slow-wave sleep when exogenously administered to freely behaving animals. It has been proposed that the native gut microflora may serve as a quasi-endogenous pool of somnogenic bacterial cell wall products given their quantity and close proximity to the intestinal portal. This proposal suggests that deliberate manipulation of the host’s intestinal flora may elicit changes in host sleep behavior. To test this possibility, we evaluated 24 h of sleep-wake behavior after depleting the gut microbiota with a 14 d broad-spectrum antibiotic regimen containing high doses of ampicillin, metronidazole, neomycin, and vancomycin.
    [Show full text]
  • Xyrem (Sodium Oxybate) Is a CNS Depressant
    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Important Administration Information for All Patients XYREM safely and effectively. See full prescribing information for • Take each dose while in bed and lie down after dosing (2.3). XYREM. • Allow 2 hours after eating before dosing (2.3). • Prepare both doses prior to bedtime; dilute each dose with approximately ¼ XYREM® (sodium oxybate) oral solution, CIII cup of water in pharmacy-provided containers (2.3). Initial U.S. Approval: 2002 • Patients with Hepatic Impairment: starting dose is one-half of the original dosage per night, administered orally divided into two doses (2.4). • WARNING: CENTRAL NERVOUS SYSTEM (CNS) DEPRESSION Concomitant use with Divalproex Sodium: an initial reduction in Xyrem dose and ABUSE AND MISUSE. of at least 20% is recommended (2.5, 7.2). --------------------DOSAGE FORMS AND STRENGTHS------------------- See full prescribing information for complete boxed warning. Oral solution, 0.5 g per mL (3) Central Nervous System Depression ----------------------------CONTRAINDICATIONS------------------------------ • Xyrem is a CNS depressant, and respiratory depression can occur with • In combination with sedative hypnotics or alcohol (4) Xyrem use (5.1, 5.4) • Succinic semialdehyde dehydrogenase deficiency (4) Abuse and Misuse • Xyrem is the sodium salt of gamma-hydroxybutyrate (GHB). Abuse or misuse of illicit GHB is associated with CNS adverse reactions, ---------------------WARNINGS AND PRECAUTIONS----------------------
    [Show full text]